Patents

Search tools Text Classification Chemistry Measure Numbers Full documents Title Abstract Claims All Any Exact Not Add AND condition These CPCs and their children These exact CPCs Add AND condition
Exact Exact Batch Similar Substructure Substructure (SMARTS) Full documents Claims only Add AND condition Add AND condition
Application Numbers Publication Numbers Either Add AND condition

Pharmaceutical composition for induction of penis erection and use of the same

Classifications

A61K38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
View 7 more classifications

Landscapes

Health & Medical Sciences Life Sciences & Earth Sciences
Show more

LV10198B

Latvia

Download PDF Find Prior Art Similar
Other languages
English
Latvian
Inventor
Gerstenberg Thomas
Fahrenkrug Jan
Ottesen Bent
Worldwide applications
1989 US 1990 IL ES DE AU RU BR JP WO HU CA DK EP AT RO SK CZ 1992 NO KR FI 1993 LV GE LT
Application LVP-93-740A events
1993-06-29
Application filed by Senetek Plc
1994-10-20
Publication of LV10198A
1995-08-20
Publication of LV10198B
Info
Patent citations (6)
Cited by (39)
Similar documents
Priority and Related Applications
External links
Espacenet
Global Dossier
Discuss

Patent Citations (6)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
US3898329A * 1971-09-17 1975-08-05 Sami I Said Vasoactive intestinal peptide, composition and method
DE3637157A1 * 1985-11-01 1987-05-21 Byk Gulden Lomberg Chem Fab Arzneimittel zur behandlung erektiler dysfunktionen
JPS62246595A * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4939224A * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
IL87055A * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
* Cited by examiner, † Cited by third party

Cited By (39)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
US5447912A * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5242391A * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
DE4117249C2 * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
US5565466A * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5482039A * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5583144A * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5731339A * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5994294A * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20020143007A1 * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6323211B1 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US5932538A * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20050065161A1 * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US6469065B1 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US20030004170A1 * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
US5947901A * 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5942545A * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6011043A * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6482426B1 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6706682B2 * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US6730065B1 * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6211156B1 * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
US6650943B1 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
CA2408417C * 2000-05-12 2009-09-15 Novalar Pharmaceuticals, Inc. Local anesthetic methods and kits
US20060211753A1 * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6885895B1 * 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
NZ560648A * 2005-03-07 2010-03-26 Mondobiotech Ag Formulation for aviptadil (vasoactive intestinal peptide, VIP)
WO2007073486A2 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2307038A4 2008-06-27 2013-03-27 Univ Duke ELASTIC PEPTIDES COMPREHENSIVE THERAPEUTIC AGENTS
PT3311828T * 2009-08-14 2021-05-05 Phasebio Pharmaceuticals Inc Péptidos intestinais vasoativos modificados
US9913748B2 2009-10-30 2018-03-13 Avner Spector Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
EP2717902B1 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
GB201221032D0 * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
GB201221046D0 * 2012-11-22 2013-01-09 Mens Health Ltd Method of diagnosis
ES2818824T3 2014-05-08 2021-04-14 Phasebio Pharmaceuticals Inc Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
EP3256151B1 2015-02-09 2020-08-05 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2019102310A1 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions
* Cited by examiner, † Cited by third party, ‡ Family to family citation

Similar Documents

Publication Publication Date Title
LV10198B 1995-08-20 Pharmaceutical composition for induction of penis erection and use of the same
Laupacis et al. 1982 Cyclosporin A: a powerful immunosuppressant
Wotherspoon et al. 1992 Low‐grade gastric B‐cell lymphoma of mucosa‐associated lymphoid tissue (MALT): a multifocal disease
Andres et al. 1975 Tubular and interstitial renal disease due to immunologic mechanisms
KR101191833B1 2012-10-16 씨형 간염 감염의 치료용［디-멜라］3-［에트발］4-시클로스포린의 이용 및 상기［디-멜라］3-［에트발］4-시클로스포린으로 구성되는 약학 조성물
Kent 1966 Staphylococcal enterotoxin gastroenteritis in rhesus monkeys
Mendelson et al. 1975 Plasma testosterone levels during chronic heroin use and protracted abstinence; A study of Hong Kong addicts
JPH07504910A 1995-06-01 新規なアミノステロール抗生物質
Kahan 1984 Cyclosporine: a powerful addition to the immunosuppressive armamentarium
Taub et al. 1972 The Effect of Localized Injection of Adjuvant Material on the Draining Lymph Node: III. Thymus Dependence
Hawkins et al. 1976 Detection by electron microscope of rod-shaped organisms in synovial membrane from a patient with the arthritis of Whipple's disease.
Martin et al. 1994 Immunoproliferative small intestinal disease: Mediterranean lymphoma and α heavy chain disease
Verhamme et al. 1988 Anisakiasis caused by herring in vinegar: a little known medical problem.
PREHN 1974 Immunological surveillance: Pro and con
Méndez et al. 2001 Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations
Otto et al. 1981 Primary intestinal lymphomas
Engert et al. 1994 Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins
Owen et al. 2022 Combination intravenous immune globulin (IVIG) and high dose steroids for treatment of immune-related myelitis in a non-small cell lung cancer patient treated with pembrolizumab and palliative radiation treatment: a case report
North 1960 Primary tumors of the retroperitoneum
Hegarty et al. 1984 Controlled trial of a thymic hormone extract (Thymostimulin) in'autoimmune'chronic active hepatitis.
Warnes 1985 Treatment of primary biliary cirrhosis
Öztürk et al. 2019 Predictable and unusual adverse effects of immunosuppression in pediatric liver transplant patients
Tsikouras et al. 1998 Two alternative solutions for the development of a marginal basin in NE Greece
Dawson 1971 Partial villous atrophy in nutritional megaloblastic anaemia corrected by folic acid therapy
Ponticelli et al. 1990 Ciclosporin in minimal-change glomerulopathy and in focal segmental glomerular sclerosis

Priority And Related Applications

Applications Claiming Priority (2)

Application Filing date Title
US07/408,754 1989-09-18 Erection-inducing methods and compositions
PCT/US1990/005237 1990-09-14 Erection-inducing methods and compositions

Concepts

machine-extracted
Download Filter table
Name Image Sections Count Query match
induction title,claims 3 0.000
pharmaceutical composition title,claims 2 0.000
penis title 1 0.000
mixture claims,abstract,description 10 0.000
impotence claims,abstract 8 0.000
inductive effect claims,abstract 6 0.000
processed proteins & peptides claims,abstract 6 0.000
Neuropeptides claims,abstract 5 0.000
Neuropeptides claims,abstract 5 0.000
neurogenic effect claims,abstract 5 0.000
Atherosclerosis claims,abstract 4 0.000
adrenergic antagonist claims,abstract 3 0.000
phentolamine claims,abstract 3 0.000
phentolamine claims,abstract 3 0.000
prazosin claims,abstract 3 0.000
prazosin claims,abstract 3 0.000
psychogenic effect claims,abstract 2 0.000
sexual effect claims 4 0.000
stimulation claims 4 0.000
vagina claims 2 0.000
Erectile Dysfunction claims 1 0.000
cervical carcinoma claims 1 0.000
erectile effect claims 1 0.000
ingredient claims 1 0.000
injection claims 1 0.000
injection claims 1 0.000
solution claims 1 0.000
substance claims 1 0.000
vasoactive effect claims 1 0.000
L-methioninamide abstract 3 0.000
c-terminal region abstract 3 0.000
histidine abstract 3 0.000
histidyl group abstract 3 0.000
intracavernous injection abstract 3 0.000
method abstract 3 0.000
penetration abstract 2 0.000
stimulating effect abstract 2 0.000
Homo sapiens Vasoactive intestinal peptide abstract 1 0.000
Vasoactive Intestinal Peptide abstract 1 0.000
Vasoactive Intestinal Peptide abstract 1 0.000
invicorp abstract 1 0.000
penile erection abstract 1 0.000
Show all concepts from the description section
Data provided by IFI CLAIMS Patent Services